NERVGEN PHARMA CORP. Adjustments For Fair Value Gains Losses
NERVGEN PHARMA CORP. (NGEN) reported Adjustments For Fair Value Gains Losses of CAD 18.96 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Income Statement › Other Income
ifrs-full:AdjustmentsForFairValueGainsLosses · last filed 2026-03-31
| Period end | Adjustments For Fair Value Gains Losses 12 month |
|---|---|
| 2025-12-31 | 18.96M CAD 40-F · filed 2026-03-31 |
| 2024-12-31 | 135.96K CAD 40-F · filed 2026-03-31 |